• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 2: Overview of Results from EMILIA and MARIANNE Trials

Article

In this clip, Dr. Swain and Dr. Newcomer discuss the results from the EMILIA trial. Dr. Swain notes that the survival benefit with the use of TDM-1 was five months.

In this clip, Dr. Swain and Dr. Newcomer discuss the results from the EMILIA trial. Dr. Swain notes that the survival benefit with the use of TDM-1 was five months. “That’s probably one of the best responses we have seen in breast cancer in almost a decade,” said Dr. Newcomer. Panelists also discuss the FDA’s recent granting of priority review to pertuzumab for use in an earlier line of therapy based on the NEOSPHERE study and TRYPHAENA studies.

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.